Comparison of efficacy and safety between long-acting growth hormone and short-acting growth hormone in isolated growth hormone deficiency: a systematic review and meta-analysis of 16 randomized controlled trials involving 2,435 pediatric patients - Takeaways - MDSpire

Comparison of efficacy and safety between long-acting growth hormone and short-acting growth hormone in isolated growth hormone deficiency: a systematic review and meta-analysis of 16 randomized controlled trials involving 2,435 pediatric patients

  • By

  • Zhen-Zhen Shen

  • Yun Huang

  • Li-Li Wu

  • Jian-Su Zhang

  • Xiao-Xia Zhang

  • June 4, 2026

  • 0 min

Share

  • 1

    Long-acting growth hormone (LAGH) shows a statistically significant improvement in height standard deviation score (Ht-SDS) compared to short-acting growth hormone (SA-GH).

  • 2

    LAGH demonstrated superior height velocity standard deviation score (HV-SDS) driven primarily by the PEG-LAGH subgroup in children with isolated growth hormone deficiency (GHD).

  • 3

    Insulin-like growth factor-1 (IGF-1) SDS levels were consistently higher in the LAGH group compared to the SA-GH group across the studies analyzed.

  • 4

    Adverse event rates were similar between LAGH and SA-GH groups, with the PEG-LAGH subgroup exhibiting the lowest incidence of adverse events.

  • 5

    LAGH is preferred for treating pediatric GHD due to its efficacy in height improvement and acceptable safety profile, despite newer formulations lacking superior growth efficacy.

Original Source(s)

Related Content